Clinical trial NCT03757936: A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors
Official title: A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (HLX10) in Combination With Recombinant Anti-VEGF Humanized Monoclonal Antibody Injection (HLX04) in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE1
Conditions: Solid Tumor
Lead sponsor: Shanghai Henlius Biotech
Sponsor class: INDUSTRY
First posted: 2018-11-29
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a single-center, open-label, dose-escalation Phase I clinical trial to evaluate the safety and the tolerability of HLX10-HLX04 combination therapy in patients with advanced solid tumors after failure of standard of care.


Eligibility criteria: Inclusion Criteria:

1. Age ≥18 years, male or female
2. Patient with histologically or cytologically confirmed advanced malignant solid tumors who have failed standard of care, or has no standard-of-care therapy or are not suitable for standard of care at the present stage;
3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1；
4. Life expectancy greater than 3 months;
5. Patient must have at least one measurable tumor lesion as defined by RECIST v1.1; the lesion concerned must not be a bone metastasis if only one target lesion is present;
6. Has adequate organ functions;
7. If the subject is a patient with hepatocellular carcinoma, Child-Pugh classification must be A.
8. A qualified patient (male or female) of childbearing potential must agree to use reliable contraceptive methods (hormonal, or barrier method or abstinence) for the course of the study and through at least 6 months after the last dose; a female patient of childbearing potential must have negative blood pregnancy test within 7 days prior to enrollment;
9. The subject must give his/her informed consent to this study prior to the trial, and voluntarily sign a written informed consent form.

Exclusion Criteria:

1. Histopathological confirmed head and neck cancer or squamous-cell lung cancer, or bleeding tendency in the tumor lesion judged by the investigator;
2. Has received antitumor therapy like radiotherapy, chemotherapy, targeted therapy, endocrinal therapy or immunotherapy, or other clinical study drug therapy within 4 months prior to the initial drug administration;
3. Has received a surgical operation on major viscera or experienced apparent trauma within 4 weeks from the initial drug administration, or experienced subcutaneous venous access device implantation within 7 days;
4. The adverse reactions which occurred in the previous antitumor treatment were not recovered to ≤ grade 1 based on CTCAE 4.03 assessment (except for hair loss);
5. Evidences of metastatic lesion in the patient's central nervous system;
6. Previously experienced ≥ grade 3 immune-related adverse event during immunotherapy;
7. Active, or history of autoimmune disease which may relapse (for example, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.);
8. Currently having or have had interstitial lung disease;
9. Uncontrollable active infection(s);
10. History of immunodeficiency, including HIV antibody positive;
11. Known active hepatitis B; or hepatitis C virus infections;
12. Has bleeding tendency;
13. History of severe cardiovascular diseases;
14. Known gastrointestinal diseases as follows:

    Gastrointestinal perforation, abdominal fistula or abdominal abscess within 6 months before signing the informed consent; History of poorly controlled or recurrent inflammatory bowel disease; Active peptic ulcers, or \> moderate esophageal varices;
15. Known hypersensitivity to Bevacizumab, or other anti-PD-1, anti-PD-L1 monoclonal antibody agents;
16. Pregnant or breastfeeding female.

Primary outcomes:
measure: Maximum Tolerated Dose (MTD) of HLX04 plus HLX10 in patients with advanced solid tumors
timeFrame: 28 days
measure: Dose Limiting Toxicity (DLT) of HLX04 plus HLX10 in patients with advanced solid tumors
timeFrame: 28 days
Secondary outcomes:
measure: PK parameters of the HLX04 plus HLX10 therapy in patients with advanced solid tumors
timeFrame: Day 1 of treatment up to 2 years
measure: PK parameters of the HLX04 plus HLX10 therapy in patients with advanced solid tumors
timeFrame: Day 1 of treatment up to 2 years
measure: Objective Response Rate (ORR) of HLX04 plus HLX10 in patients with advanced solid tumors
timeFrame: Day 1 of treatment up to 2 years
measure: Disease Control Rate (DCR) of HLX04 plus HLX10 in patients with advanced solid tumors
timeFrame: Day 1 of treatment up to 2 years
measure: Duration of Response (DOR) of HLX04 plus HLX10 in patients with advanced solid tumors
timeFrame: Day 1 of treatment up to 2 years
measure: Progression-Free Survival (PFS) of HLX04 plus HLX10 in patients with advanced solid tumors
timeFrame: Day 1 of treatment up to 2 years
measure: Overall Survival (OS) of HLX04 plus HLX10 in patients with advanced solid tumors
timeFrame: Day 1 of treatment up to 2 years
measure: Immunogenicity
timeFrame: Day 1 of treatment up to 2 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai East Hospital
Study officials:
References: